EHA Abstrakt 2019
Kommande presentationer vid EHA
Data från HORIZON studien kommer att presenteras av Professor Paul Richardson den 16 juni klockan 08.45 (CET) under en session kallad “Novel strategies in multiple myeloma”. Paul Richardson MD, RJ Corman professor i medicin vid Harvard Medical School och direktör för klinisk forskning vid Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, USA.
Postrarna kommer att publiceras fredagen den 14 juni klockan 09.30 (CET) och presenteras mellan klockan 17.30 – 19.00 samma dag.
Oncopeptides kommer även att vara värd för ett symposium vid EHA den 13 juni mellan 18.45 – 20.45 (CET) i Amsterdam RAI Hall 3B, under titeln ”Challenging the Treatment Paradigm in Multiple Myeloma”.
De fyra abstrakt som finns i EHAs Abstract book.
HORIZON (OP-106): Updated efficacy and safety of melflufen in relapsed / refractory multiple myeloma (RRMM) patients refractory to daratumumab (DARA) and/or pomalidomide (POM)
Tema: Myeloma and other monoclonal gammopathies – Clinical
Session titel: Novel strategies in multiple myeloma
Abstrakt kod – S 1605
ANCHOR (OP-104): A phase 1/2 study update of melflufen and dexamethasone plus bortezomib or daratumumab in in relapsed / refractory multiple myeloma patients refractory to an IMiD or a proteasome inhibitor
Tema: Myeloma and other monoclonal gammopathies – Clinical
Session titel Myeloma and other monoclonal gammopathies – Clinical
Abstrakt kod – 608
O-12-M1: An evaluation of time to next treatment in melflufen and dexamethasone treated patients with relapsed / refractory multiple myeloma
Tema: Myeloma and other monoclonal gammopathies – Clinical
Session titel: Myeloma and other monoclonal gammopathies – Clinical
Abstrakt kod – PF 628
Tolerability of treatments for relapsed / refractory multiple myeloma: A systematic review
Tema: Quality of life, palliative & supportive care, ethics and health economics
Session titel: Quality of life, palliative & supportive care, ethics and health economics
Abstrakt kod – PF 726